A quadrivalent vaccine against human papillomavirus prevented anogenital diseases in young women
- The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Read, Tim R. H.; Hocking, Jane S.; Chen, Marcus Y.; Donovan, Basil; Bradshaw, Catriona S.; Fairley, Christopher K. // Sexually Transmitted Infections;Dec2011, Vol. 87 Issue 7, p544
Background Australia provided free quadrivalent human papillomavirus vaccines to 12-18-year-old girls and women aged â‰¤26 years from mid-2007 until the end of 2009. After this time, only girls aged 12-13 years had access to free vaccines. Methods Before and after the study, of the...
- Papillomavirus vaccine progress continues. Moyer, Paula // Dermatology Times;Mar1996, Vol. 17 Issue 3, p63
Focuses on doctor Douglas Lowy's discussion on researchers' continued exploration of the feasibility of papillomavirus vaccines. Report at the 54th annual meeting of the American Academy of Dermatology; Potential in preventing external genital warts and cervical cancer.
- Quadrivalent Human Papillomavirus (HPV) Types 6, 11, 16, 18 Vaccine for the Prevention of Genital Warts in Males. Garnock-Jones, Karly; Giuliano, Anna // Drugs in R&D;2012, Vol. 12 Issue 4, p235
The article presents a discussion of the efficacy of human papillomavirus (HPV) vaccine for the prevention of genital warts caused by HPV types 6, 11, 16, and 18 in male, adapted from an article published in the 2011 issue of the journal "Drugs in R&D."
- HPV vaccine given to males prevents genital warts. // Contemporary Pediatrics;Mar2011, Vol. 28 Issue 3, p10
No abstract available.
- COMMENTARY: A quadrivalent vaccine against human papillomavirus prevented anogenital diseases in young women. Andrews, Jeff // ACP Journal Club;Nov/Dec2007, Vol. 147 Issue 3, p71
The author reflects upon a study evaluating the effectiveness of quadrivalent vaccine against human papillomavirus (HPV), in preventing anogenital diseases in young women. He comments on the limited length of the study's follow-ups and suggests the requirement of longer follow-up for evaluating...
- Re: Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women. BREWER, NOEL T.; REITER, PAUL L. // JNCI: Journal of the National Cancer Institute;Oct2010, Vol. 102 Issue 19, p1517
The authors comment on a study that showed the efficacy of human papillomavirus (HPV)-6/11/16/18 vaccine against all HPV-associated genital diseases in young women, such as vulvar and cervical intraepithelial neoplasia, adenocarcinoma in situ and genital warts. The study participants were...
- Warts and all at last: HPV vaccination. Hammond, Phil // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;12/3/2011, Vol. 343 Issue 7834, p1153
The author discusses the health campaign of the Great Britain government such as offering human papilloma virus (HPV) vaccination. He mentions the editorial in "Lancet" which appeared in October 2006 that argues on the protection that Gardasil offered against HPV types 6, 11, 16, and 18 that...
- Quadrivalent Human Papillomavirus (HPV) Types 6, 11, 16, 18 Vaccine: For the Prevention of Genital Warts in Males. Garnock-Jones, Karly P.; Giuliano, Anna R. // Drugs;2011, Vol. 71 Issue 5, p591
The quadrivalent HPV types 6, 11, 16, 18 vaccine (GardasilÂ®) is a recombinant vaccine comprising purified virus-like particles derived from the L1 capsid proteins of HPV types 6, 11, 16 and 18. The vaccine was highly immunogenic. Geometric mean titres (GMTs) and seroconversion rates for all...
- HPV/cancer jab switch could save millions of pounds a year. // Community Practitioner;Sep2011, Vol. 84 Issue 9, p7
The article discusses the study by Great Britain Health Protection Agency (HPA), which reveals that the National Health Service (NHS) of Great Britain could save cash if it replaced cervical cancer vaccines with the quadrivalent human papillomavirus (HPV) vaccine called Gardasil which also...